Moderna's stock price has surged 700% this year amid excitement over its experimental cancer vaccine. However, the company's recent earnings reveal that its revenue growth remains largely driven by strong international demand for its Covid vaccines. Moderna has raised its full-year revenue outlook based on this continued Covid vaccine performance. While the cancer vaccine hype fuels investor enthusiasm, the financial results confirm that Covid-related sales are still the main revenue source for now.
Moderna's market capitalization stands at $96.40 billion as of November 6, 2026, 20:11 WIB, highlighting its significant size in the health sector. On Pluang, the stock price is USD 228.67, down 5.30% for the day, with a trading volume of 11,879,068 shares and a typical hold time of 58 days. Despite recent earnings showing Covid vaccines still driving revenue, investor activity on Pluang leans 68% towards buying, reflecting ongoing interest in the stock.
Moderna increased its revenue outlook for 2026, now expecting growth between 15% and 25%, up from a previous forecast of 10%. The company, known for its mRNA COVID-19 vaccine Spikevax, cited strong sales as the reason for the optimistic update. This ...
Moderna exceeded third-quarter revenue and earnings expectations, reporting $1.31 billion in revenue and 38 cents earnings per share, compared to analyst estimates of $885.1 million and a loss of $1.25 per share. The company raised its 2026 revenue g...
On November 6, Moderna, Humana, and Elanco will release earnings reports that could impact their stock rallies. Humana's Medicare Advantage update is crucial for retirees, with a focus on medical costs and membership trends. Elanco faces supply chall...
Moderna's stock is rated Strong Sell at $220.83, with a valuation around $60 per share, implying a 73% downside. This is despite promising Phase 3 melanoma trial results showing a 42% reduction in relapse or death when using intismeran with Keytruda....
Moderna's stock rose 5% ahead of its earnings report, continuing a strong 685% gain this year, driven by its mRNA vaccine focus and oncology pipeline. Pfizer's shares fell 0.8% despite beating Q3 revenue estimates and raising its 2026 guidance, as CO...
